Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anisodine hydrobromide for non-arteritic anterior ischemic optic neuropathy
ChiCTR2000030781Phase 4Not yet recruiting
- Sponsor
- The First Medical Center of Chinese PLA General Hospital
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anisodine in non-arteritic anterior ischemic optic neuropathy (NAION) (2 arms), sponsored by The First Medical Center of Chinese PLA General Hospital. Primary endpoint: Total effective rate of disease treatment at 6 months. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
anisodine
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on ChiCTR2000030781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030781.